A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)

Official Title

A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Relapsed or refractory Hodgkin lymphoma following failure of standard frontline chemotherapy for the treatment of classical Hodgkin lymphoma - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion Criteria:
  1. - Previously treated with brentuximab vedotin, immune-oncology agents, or received an allogeneic or autologous stem cell transplant - Documented history of a cerebral vascular event - History of another invasive malignancy that has not been in remission for at least 3 years - History of progressive multifocal leukoencephalopathy (PML)


Ranjana Advani
Ranjana Advani
Lymphoma specialist, Hematologist-Oncologist
Saul A. Rosenberg, MD, Professor of Lymphoma
Hans-Christoph Becker, MD, FSABI, FSCCT
Clinical Professor, Radiology

Contact us to find out if this trial is right for you.